In the last trading session, 4.29 million Coherus Biosciences Inc (NASDAQ:CHRS) shares changed hands as the company’s beta touched 0.86. With the company’s per share price at $1.37 changed hands at $0.15 or 12.30% during last session, the market valuation stood at $152.83M. CHRS’s last price was a discount, traded about -170.07% off its 52-week high of $3.70. The share price had its 52-week low at $0.66, which suggests the last value was 51.82% up since then. When we look at Coherus Biosciences Inc’s average trading volume, we note the 10-day average is 4.33 million shares, with the 3-month average coming to 2.89 million.
Analysts gave the Coherus Biosciences Inc (CHRS) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.57. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended CHRS as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Coherus Biosciences Inc’s EPS for the current quarter is expected to be -0.18.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Coherus Biosciences Inc (NASDAQ:CHRS) trade information
Instantly CHRS was in green as seen at the end of in last trading. With action 25.69%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -58.86%, with the 5-day performance at 25.69% in the green. However, in the 30-day time frame, Coherus Biosciences Inc (NASDAQ:CHRS) is 83.89% up. Looking at the short shares, we see there were 33.04 million shares sold at short interest cover period of 12.34 days.
The consensus price target for the stock as assigned by Wall Street analysts is 9, meaning bulls need an upside of 84.78% from its current market value. According to analyst projections, CHRS’s forecast low is 7 with 11 as the target high. To hit the forecast high, the stock’s price needs a -702.92% plunge from its current level, while the stock would need to soar -410.95% for it to hit the projected low.
Coherus Biosciences Inc (CHRS) estimates and forecasts
Data shows that the Coherus Biosciences Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -22.16% over the past 6 months, a 64.65% in annual growth rate that is considerably higher than the industry average of 17.70%. Year-over-year growth is forecast to reach -0.65% down from the last financial year.
Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of 43.88M. 2 analysts are of the opinion that Coherus Biosciences Inc’s revenue for the current quarter will be 66.55M. The company’s revenue for the corresponding quarters a year ago was 91.52M and 77.06M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -52.06%. The estimates for the next quarter sales put growth at -13.64%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 4.73%. The 2024 estimates are for Coherus Biosciences Inc earnings to increase by 113.97%.
CHRS Dividends
Coherus Biosciences Inc is expected to release its next quarterly earnings report in January.
Coherus Biosciences Inc (NASDAQ:CHRS)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 1.39% of Coherus Biosciences Inc shares while 70.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 71.08%. There are 70.09% institutions holding the Coherus Biosciences Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 10.4236% of the shares, roughly 11.75 million CHRS shares worth $20.33 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 9.4035% or 10.6 million shares worth $18.34 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jun 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 3.33 shares estimated at $4.56 million under it, the former controlled 2.89% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.57% of the shares, roughly 2.96 shares worth around $4.06 million.
